80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

Enriqueta Felip, Nassar Altorki, Chi Zhou, E. Vallieres, Ihor Vynnychenko, A. Akopov, Alex Martínez‐Martí, Antonio Chella, Igor Bondarenko, G. Ursol, E. Levchenko, N. Kislov, Rüdiger Liersch, R. Belleli, Virginia McNally, E. Bennett, B.J. Gitlitz, H. Wakelee